Clinicopathological Study of Gastrointestinal Stromal Tumour

Authors

  •   S. Karthikeyan Department of Pathology, Coimbatore Medical College, Coimbatore - 641014, Tamil Nadu
  •   A. Dhanalakshmi Department of Pathology, Coimbatore Medical College, Coimbatore - 641014, Tamil Nadu

DOI:

https://doi.org/10.65129/health.v1i3.90

Keywords:

Gastrointestinal Stromal Tumor (GIST); Tyrosine Kinase receptor Inhibitor (TKI); Risk Classification; Prognosis; Outcome

Abstract

Gastrointestinal Stromal Tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract, arising predominantly in the stomach and small intestine. They originate from the interstitial cells of Cajal or related stem cells and are characterized by mutations in the KIT or PDGFRA genes. Clinically, GISTs may present with nonspecific symptoms such as abdominal pain, gastrointestinal bleeding, or may be incidentally discovered. Histologically, they display spindle cell, epithelioid, or mixed morphology, and immunohistochemical staining for CD117 (KIT), DOG1, and CD34 aids in diagnosis. Risk stratification is based on tumor size, mitotic index, and anatomical location. Surgical resection is the primary treatment for localized disease, while targeted therapy with tyrosine kinase inhibitors (e.g., imatinib) is effective in advanced or metastatic cases. Recent advancements in molecular diagnostics and targeted therapy have significantly improved the prognosis of GIST patients.

Downloads

Download data is not yet available.

Downloads

Published

2025-09-28

How to Cite

Karthikeyan, S., & Dhanalakshmi, A. (2025). Clinicopathological Study of Gastrointestinal Stromal Tumour. Journal of Health and Technology, 1(3), 151–157. https://doi.org/10.65129/health.v1i3.90

Issue

Volume 1, Issue 3, September 2025

Section

Research Article

License

Copyright (c) 2026 Journal of Health and Technology

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Crossref
Scopus
Google Scholar
Europe PMC

References

1. Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol. 1983; 7:507-19. https://doi.org/10.1097/00000478-198309000-00001 PMid:6625048.

2. Rammohan A, Sathya Nesan J, Rajendran K, et al. A gist of gastrointestinal stromal tumors: A review. World J Gastrointestinal Oncol. 2013; 5:102-12. https://doi.org/10.4251/wjgo.v5.i6.102 PMid:23847717 PMCid: PMC3708046.

3. Kind Blom LG, Remotti HE, Aldenborg F, et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol.

1998; 152:1259-69.

4. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002; 33:459-465

5. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998; 279:577-80. https://doi.org/10.1126/science.279.5350.577 PMid:9438854.

6. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol. 2005; 29(1):52-68. [PubMed]

7. Corbin KS, Kindler HL, Liauw SL. Considering the role of radiation therapy for gastrointestinal stromal tumor. Onco Targets Ther. 2014; 7:713-8. https://doi.org/10.2147/OTT.S36873 PMid:24872712 PMCid:PMC4026585.

8. Wu PC, Langerman A, Ryan CW, et al. Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era. Surgery. 2003; 134:656-65. https://doi.org/10.1016/ S0039-6060(03)00315-5

9. Benjamin RS, Casali PG. Adjuvant imatinib for GI stromal tumors: When and for how long? J Clin Oncol.

2016; 34:215-8. https://doi.org/10.1200/JCO.2015.64.0102 PMid:26644523.

10. DeMatteo RP. Nano neoadjuvant therapy of gastrointestinal stromal tumor (GIST). Ann Surg Oncol. 2009; 16:799800. https://doi.org/10.1245/s10434-009-0316-9 PMid:19169754.

11. Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumors after failure of imatinib and sunitinib (GRID): an international, multicenter, randomized, placebo controlled, phase 3 trial. Lancet. 2013; 381:295-302.

12. Eisenberg BL. The SSG XVIII/AIO trial: results change the current adjuvant treatment recommendations for gastrointestinal stromal tumors. Am J Clin Oncol. 2013; 36:89-90. https://doi.org/10.1097/COC.0b013e31827a7f55 PMid:23334483.

13. Gronchi A, Blay JY, Trent JC. The role of high dose imatinib in the management of patients with gastrointestinal stromal tumor. Cancer. 2010; 116:1847-58. https://doi.org/10.1002/ cncr.24944 PMid:20166214.

14. Heinrich MC, von Mehren M, Demetri GD, et al. A phase 2 study of ponatinib in patients (pts) with advanced gastrointestinal stromal tumors (GIST) after failure of tyrosine kinase inhibitor (TKI) therapy: Initial report. J Clin Oncol. 2014; 32:10506. https://doi.org/10.1200/jco.2014.32.15_suppl.10506

15. Mulet-Margalef N, Garcia-Del-Muro X. Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives. Onco Targets Ther. 2016; 9:7573-82. https://doi.org/10.2147/OTT.S101385 PMid:28008275 PMCid: PMC5171199.

16. Beltran MA, Cruces KS. Primary tumors of jejunum and ileum as a cause of intestinal obstruction: a case control study. Int J Surg. 2007; 5:183-91. https://doi.org/10.1016/j.ijsu.2006.05.006 PMid:17509501.